Accelmed Expands Senior Team With Two New Partners
Accelmed Partners ("Accelmed"), a private equity firm focused on acquiring and investing in U.S. commercial stage, lower middle market HealthTech companies, today announced the expansion of its senior leadership team with the addition of two industry veterans. Eric Tansky, former Managing Director in Oppenheimer & Co.'s Medical Technology practice, has joined the firm as General Partner, and Stephen Rubin, former co-head of Proskauer's Private Equity Group, as Partner.
"Eric and Steve are both deeply experienced and well-respected in their fields, are of high character, and, most importantly, share Accelmed's commitment to seeking to provide strong risk-adjusted returns to investors by capturing dynamic HealthTech investment opportunities," said Dr. Uri Geiger, Founder and Managing Partner of Accelmed. "Having known both Eric and Steve for some time, I've seen first-hand their transaction expertise, strong relationships and industry insights, and can confidently say how fortunate we are to be able to leverage their collective skillsets as we build upon the successful recent close of our second fund."
Mr. Tansky added, "Accelmed has proven itself as a strong investment and operational partner to management teams at the companies in which it invests, and I look forward to working closely with Uri and the entire team to continue driving significant value for our portfolio companies and investors in the years to come."
Mr. Rubin commented, "I am pleased to join Accelmed at this exciting time in the industry's evolution - when there is high demand for partnerships between innovative HealthTech companies and value-add investment partners such as Accelmed."
In addition to Messrs. Tansky and Rubin, Accelmed has also bolstered its Executives Network with the additions of Lewis (Lew) Pell and Stanley Stern, veterans in the fields of medical technology and investment banking, respectively. Messrs. Pell and Stern will join Accelmed's existing Executives Network members, all of whom have successfully built, led nd sold businesses and assist Accelmed in identifying and analyzing potential investment opportunities. The expansion of Accelmed's senior team and Executives Network follows the recent close of Accelmed Fund II, LP at a hard cap of $400 million, and the firm's investments in TearLab, NeuroPace (which recently went public) and MedMinder.
Eric Tansky Biography
Mr. Tansky has more than 20 years of experience in the medical technology field as both an investment banker and sales professional. During his career as an investment banker, Mr. Tansky worked at both bulge bracket and middle market firms and led a wide range of strategic and financial transactions. Prior to a career in the industry, Mr. Tansky served in the U.S. Navy as a Submarine Officer and Navy Diver.
Stephen Rubin Biography
Mr. Rubin has spent more than 30 years in private equity and has been involved in all types of acquisition transactions, including auctions and privately negotiated transactions, acquisitions from public and private companies, and acquisitions out of bankruptcy. He has extensive experience in private equity and debt offerings, as well as senior and subordinated loan transactions. He is the former President of the Friends of the Israel Defense Forces (FIDF).
Lewis Pell Biography
Known as one of the world's most recognized HealthTech investors, Mr. Pell has served as the lead investor or co-founder of 24 medical device manufacturers, eight of which have been sold for a collective net gain of $1.6 billion. He was the co-founder of Machida America; founder of Pentax (News - Alert) Precision Instruments, which was sold to Asahi Optical; co-founder of American Endoscopy, which was acquired by C.R. Bard; co-founder of Versaflex, which was acquired by Medtronic; and co-founder of Heart Technology to create and launch the Rotablator, which went public before being acquired by Boston Scientific. He has also co-founded several Israeli companies, including InStent, which was sold to Medtronic; Disk-O-Tech, which was sold to Kyphon; and BioSense, which sold to Johnson & Johnson.
Stanley Stern Biography
Mr. Stern is the former Head of Investment Banking at Oppenheimer & Co. He previously served as President of STI Ventures Advisory USA Inc., a venture capital firm focusing on technology investments, and earlier spent over 20 years at CIBC Oppenheimer where he started the technology banking group. He is a director at Accelmed portfolio company, Keystone Dental, is Chairman of the Board of Directors of AudioCodes (News - Alert), and also serves on the boards of Ekso Bionics, Ormat and Radware.
About Accelmed Partners
Accelmed is a U.S.-based private equity firm focused on acquiring and investing in U.S. commercial stage, lower middle market HealthTech companies. Since 2009, Accelmed has deployed over $400 million into companies spanning medical devices, diagnostics, digital health and technology-enabled healthcare services. Accelmed seeks to accelerate value and scale innovation across the HealthTech field by bringing to bear the team's industry experience, operational and financial expertise, and strong global relationships. For more information, please visit https://www.accelmed.com/.